Acquisition of drug resistance in basal cell nevus syndrome tumors through basal to squamous cell carcinoma transition
Preprint
Abstract
While basal cell carcinomas (BCCs) arise from ectopic hedgehog pathway activation and can be treated with pathway inhibitors, sporadic BCCs display high resistance rates while tumors arising in Gorlin syndrome patients with germline Patched ( PTCH1 ) mutations are uniformly suppressed by inhibitor therapy. In rare cases, Gorlin syndrome patients on long-term inhibitor therapy will develop individual resistant tumor clones that rapidly progress, but the basis of this resistance remains unstudied. Here we report a case of an SMO i -resistant tumor arising in a Gorlin patient on suppressive SMO i for nearly a decade. Using a combination of multi-omics and spatial transcriptomics, we define the tumor populations at the cellular and tissue level to conclude that Gorlin tumors can develop resistance to SMO i through the previously described basal to squamous cell carcinoma transition (BST). Intriguingly, through spatial whole exome genomic analysis, we nominate PCYT2, ETNK1, and the phosphatidylethanolamine biosynthetic pathway as novel genetic suppressors of BST resistance. These observations provide a general framework for studying tumor evolution and provide important clinical insight into mechanisms of resistance to SMO i for not only Gorlin syndrome but sporadic BCCs as well.Keywords
All Related Versions
- Published version: Journal of Investigative Dermatology, 144 (6), 1368.
This publication has 21 references indexed in Scilit:
- Deciphering the cells of origin of squamous cell carcinomasNature Reviews Cancer, 2018
- Genomic Stability in Syndromic Basal Cell CarcinomaJournal of Investigative Dermatology, 2018
- Ethanolamine and Phosphatidylethanolamine: Partners in Health and DiseaseOxidative Medicine and Cellular Longevity, 2017
- Squamous Change in Basal-Cell Carcinoma with Drug ResistanceNew England Journal of Medicine, 2015
- Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell CarcinomaCancer Cell, 2015
- Meclizine Inhibits Mitochondrial Respiration through Direct Targeting of Cytosolic Phosphoethanolamine MetabolismJournal of Biological Chemistry, 2013
- Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus SyndromeNew England Journal of Medicine, 2012
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2012
- Basal Cell Carcinomas in Mice Overexpressing Sonic HedgehogScience, 1997
- Clonal growth of normal human epidermal keratinocytes in a defined mediumJournal of Cellular Physiology, 1982